Healthy Nevada Project Sharing Clinical Results with Consenting Participants
02. Oktober 2018 08:00 ET
|
Renown Health
Reno, Nev., Oct. 02, 2018 (GLOBE NEWSWIRE) -- The Healthy Nevada Project led by Renown Institute for Health Innovation (Renown IHI) is announcing another landmark milestone – returning clinical...
Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer
10. September 2018 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
ProLynx announces allowance of additional U.S. patent for PLX038, a novel DNA damage response enhancer
10. April 2018 09:00 ET
|
ProLynx LLC
SAN FRANCISCO, April 10, 2018 (GLOBE NEWSWIRE) -- Prolynx LLC (San Francisco, CA) announced it received a Notice of Allowance for its DNA damage enhancer PLX038 (PEG~SN-38), currently in Phase 1...
Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO
06. Juni 2016 10:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., June 06, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), reported today updated Phase 1 data from its DNA...
BRCA Gene Testing-Based Breast Cancer and Ovarian Cancer Keynote Speaker, Advocate, Advisor and 'Previvor' Launches 'BRCA Believer' Brand Inspired by Personal Experience
22. Juli 2014 14:23 ET
|
BRCA Believer
SAN DIEGO, CA--(Marketwired - July 22, 2014) - BRCA gene testing-based breast cancer and ovarian cancer keynote speaker, advocate, advisor and "previvor," Merilee Kern, today announced the launch of...
CONTEMPORARY OBSTETRICS AND GYNECOLOGY OF DAYTON ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
30. September 2013 10:34 ET
|
Genetic Technologies Group
DAYTON, Ohio, Sept. 30, 2013 (GLOBE NEWSWIRE) -- Contemporary Obstetrics & Gynecology, part of the Providence Medical Group, today announced the availability of the BREVAGen™ predictive risk...
PEARL W. YEE, M.D. INC. OF SAN FRANCISCO ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
16. September 2013 10:08 ET
|
Genetic Technologies Group
SAN FRANCISCO, Sept. 16, 2013 (GLOBE NEWSWIRE) -- Pearl Yee, MD, FACOG and clinical professor at the University of California, San Francisco, is pleased to announce that her private practice, Pearl W....
OB/GYN ASSOCIATES IN LEWISBURG, PA ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
26. August 2013 13:06 ET
|
Genetic Technologies Group
SUNBURY, PA., Aug. 26, 2013 (GLOBE NEWSWIRE) -- Russell Stankiewicz, MD, FACOG, CCD, NMCP, is pleased to announce that OB/GYN Associates of Lewisburg, P.C. in Lewisburg, PA is now offering the...
THE HEWITT CENTER FOR BREAST WELLNESS AT GRIFFIN HOSPITAL IN DERBY, CT LAUNCHES HIGH-RISK PROGRAM INCLUDING STATE-OF-THE-ART BREAST CANCER SCREENING OPTIONS
24. Juni 2013 12:16 ET
|
Genetic Technologies Group
DERBY, Conn., June 24, 2013 (GLOBE NEWSWIRE) -- Denise Barajas, MD, medical director at The Hewitt Center for Breast Wellness in Derby, CT, has launched a high-risk breast cancer program that includes...
Atossa Genetics to Sponsor Screenings of Decoding Annie Parker at the Seattle International Film Festival on June 6 and 8, 2013
21. Mai 2013 08:30 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - May 21, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, is sponsoring two screenings of the new film Decoding Annie Parker at the Seattle...